Concepedia

Rebecca Hong Thibodeau

RH

Statistics

Publications

3

Citations

257

H-Index

3

Active since

2018

Affiliations

Genesys (United States)(Current)

Rebecca Hong Thibodeau is an author at Genesys (United States) specializing in pi3k signaling, oncology, and phase iii clinical trials.

Publications per year

2018–2024

3

Publications

3

Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα

Emily J. Hanan, Marie-Gabrielle Braun, Robert A. Heald et al. · Journal of Medicinal Chemistry · 2022 · 134 citations · Full text

, , +14

The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function

Sairy Hernandez, Rebecca Hong Thibodeau, Xiangnan Du et al. · Cell Reports · 2018 · 112 citations · Full text

, , +17

Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human

Laurent Salphati, Jodie Pang, Emile G. Plise et al. · Xenobiotica · 2024 · 11 citations

, , +13

1–3 of 3